Collagenase treatment does not impair fiber contractile function in muscle biopsies from children with cerebral palsy

胶原酶治疗不会损害脑瘫患儿肌肉活检样本中的肌纤维收缩功能。

阅读:1

Abstract

Cerebral palsy (CP) often presents with increased passive stiffness of the skeletal muscles, primarily due to increased collagen in the extracellular matrix. Collagenase from Clostridium histolyticum (CCH), an enzyme that degrades collagen, is used clinically to treat fibrotic conditions such as Dupuytren's contracture and Peyronie's disease. Although prior work demonstrated reduced passive stiffness in muscle bundles from children with CP following CCH incubation, its effects on active contractile properties remain unknown. Thus, this study was aimed at investigating the maximal active force, calcium sensitivity, and myofibrillar protein content (myosin and actin) after CCH incubation. Nine muscle biopsies from children with CP were used for skinned fiber mechanical testing at an average sarcomere length of 2.4 μm, and for myosin and actin analysis using 12% SDS-PAGE. Maximal active stress (control 59.8 ± 24.2 kPa; CCH 63.2 ± 24.5 kPa; p = 0.51) and pCa₅₀ (control 6.04 ± 0.10; CCH 5.99 ± 0.18; p = 0.43) did not significantly differ. Similarly, the normalized myosin (control 1.000 ± 0.167, CCH 1.004 ± 0.178; p = 0.93) and actin (control 1.000 ± 0.336, CCH 1.107 ± 0.330; p = 0.231) content did not differ between conditions. These results suggest that collagenase does not impair the contractile function in muscle fibers from children with CP and thus might be a feasible treatment to reduce stiffness due to muscle fibrosis. Research into whole-muscle force transmission following collagenase treatment is needed to evaluate its clinical viability.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。